| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total operating revenue | 136,564 | 119,802 | 104,406 | 99,901 |
| Direct costs-Health Care Patient Service | 54,572 | 51,150 | - | - |
| Direct costs-Dispensary Revenue | 63,072 | 51,086 | - | - |
| Direct costs | - | - | 87,157 | 85,209 |
| Direct costs-Clinical Research Trials And Other Revenue | 0 | 65 | - | - |
| Selling, general and administrative expense | 25,251 | 26,907 | 25,376 | 26,646 |
| Depreciation and amortization | 1,723 | 1,805 | 1,784 | 1,573 |
| Total operating expenses | 144,618 | 131,013 | 114,317 | 113,754 |
| Loss from operations | -8,054 | -11,211 | -9,911 | -13,853 |
| Interest expense, net | 1,920 | 1,870 | 5,570 | 2,225 |
| Change in fair value of derivative warrant liabilities | 150 | 53 | 43 | -20 |
| Change in fair value of conversion option derivative liabilities | -5,977 | -3,987 | -3,309 | - |
| Other, net | -403 | -19 | -752 | -55 |
| Total other non-operating loss | -8,450 | -5,929 | -9,674 | -2,260 |
| Loss before provision for income taxes | -16,504 | -17,140 | -19,585 | -16,113 |
| Income tax benefit | 0 | -131 | - | - |
| Net loss | -16,504 | -17,009 | -19,585 | -16,113 |
| Basic (in dollars per share) | -0.14 | -0.15 | -0.21 | -0.18 |
| Basic (in shares) | 97,474,797 | 93,203,665 | 77,098,825 | 75,524,823 |
| Diluted (in dollars per share) | -0.14 | -0.15 | -0.21 | -0.18 |
| Diluted (in shares) | 97,474,797 | 93,203,665 | 77,098,825 | 75,524,823 |
Oncology Institute, Inc. (DFPH)
Oncology Institute, Inc. (DFPH)